The US Food and Drug Administration has given emergency use authorization (EUA) to a blood purification system to help patients filter out excess proteins known as cytokines. Physicians have reported “cytokine storms” in response to COVID-19 that could account for why some patients relapse and die from organ failure after initially showing symptoms of improving.
The agency on 9 April sent a letter to Terumo Corp. giving the company EUA for the its Spectra Optia Apheresis System with the Depuro D2000 Adsorption Cartridge....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?